MGX Key Statistics, Chart & Performance
The current stock price of MGX is 1.69 USD. In the past month the price decreased by -1.74%. In the past year, price decreased by -43.1%.
MGX Technical Analysis
MGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGX. No worries on liquidiy or solvency for MGX as it has an excellent financial health rating, but there are worries on the profitability.
MGX Financial Highlights
Over the last trailing twelve months MGX reported a non-GAAP Earnings per Share(EPS) of -2.4. The EPS increased by 4.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.79% | ||
| ROE | -49.73% | ||
| Debt/Equity | 0 |
MGX Forecast & Estimates
9 analysts have analysed MGX and the average price target is 9.52 USD. This implies a price increase of 463.31% is expected in the next year compared to the current price of 1.69.
For the next year, analysts expect an EPS growth of 9.05% and a revenue growth -46.01% for MGX
MGX Ownership
About MGX
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2024-02-09. The company is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
Company Info
METAGENOMI THERAPEUTICS INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 124
Phone: 15108714880
METAGENOMI THERAPEUTICS INC / MGX FAQ
Can you describe the business of METAGENOMI THERAPEUTICS INC?
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2024-02-09. The company is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
What is the stock price of METAGENOMI THERAPEUTICS INC today?
The current stock price of MGX is 1.69 USD. The price decreased by -3.43% in the last trading session.
Does MGX stock pay dividends?
MGX does not pay a dividend.
How is the ChartMill rating for METAGENOMI THERAPEUTICS INC?
MGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MGX stock listed?
MGX stock is listed on the Nasdaq exchange.
Is METAGENOMI THERAPEUTICS INC (MGX) expected to grow?
The Revenue of METAGENOMI THERAPEUTICS INC (MGX) is expected to decline by -46.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for METAGENOMI THERAPEUTICS INC?
METAGENOMI THERAPEUTICS INC (MGX) currently has 124 employees.